MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma

The emergence of drug resistance continues to be a major hurdle towards improving patient outcomes for the treatment of Multiple Myeloma. MTI-101 is a first-in-class peptidomimetic that binds a CD44/ITGA4 containing complex and triggers necrotic cell death in multiple myeloma cell lines. In this rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Emmons, Michael F., Anreddy, Nagaraju, Cuevas, Javier, Steinberger, Kayla, Yang, Shengyu, McLaughlin, Mark, Silva, Ariosto, Hazlehurst, Lori A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457439/
https://www.ncbi.nlm.nih.gov/pubmed/28578393
http://dx.doi.org/10.1038/s41598-017-02713-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457439/
https://www.ncbi.nlm.nih.gov/pubmed/28578393
http://dx.doi.org/10.1038/s41598-017-02713-0

Ejemplares similares